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Kocsis T, Trencsenyi G, Szabo K, Baan JA, Muller G, Mendler
L, Garai I, Reinauer H, Deak F, Dux L, Keller-Pinter A. Myostatin
propeptide mutation of the hypermuscular Compact mice decreases
the formation of myostatin and improves insulin sensitivity. Am J
Physiol Endocrinol Metab 312: E150–E160, 2017. First published
December 13, 2016; doi:10.1152/ajpendo.00216.2016.—The TGF
family member myostatin (growth/differentiation factor-8) is a nega-
tive regulator of skeletal muscle growth. The hypermuscular Compact
mice carry the 12-bp Mstn(Cmpt-dl1Abc) deletion in the sequence
encoding the propeptide region of the precursor promyostatin, and
additional modifier genes of the Compact genetic background con-
tribute to determine the full expression of the phenotype. In this study,
by using mice strains carrying mutant or wild-type myostatin alleles
with the Compact genetic background and nonmutant myostatin with
the wild-type background, we studied separately the effect of the
Mstn(Cmpt-dl1Abc) mutation or the Compact genetic background on
morphology, metabolism, and signaling. We show that both the
Compact myostatin mutation and Compact genetic background ac-
count for determination of skeletal muscle size. Despite the increased
musculature of Compacts, the absolute size of heart and kidney is not
influenced by myostatin mutation; however, the Compact genetic
background increases them. Both Compact myostatin and genetic
background exhibit systemic metabolic effects. The Compact mu-
tation decreases adiposity and improves whole body glucose up-
take, insulin sensitivity, and 18FDG uptake of skeletal muscle and
white adipose tissue, whereas the Compact genetic background has
the opposite effect. Importantly, the mutation does not prevent the
formation of mature myostatin; however, a decrease in myostatin
level was observed, leading to altered activation of Smad2, Smad1/
5/8, and Akt, and an increased level of p-AS160, a Rab-GTPase-
activating protein responsible for GLUT4 translocation. Based on
our analysis, the Compact genetic background strengthens the
effect of myostatin mutation on muscle mass, but those can
compensate for each other when systemic metabolic effects are
compared.
myostatin; Compact mice; skeletal muscle; insulin resistance; 2-de-
oxy-2-[18F]fluoro-D-glucose
MYOSTATIN [growth/differentiation factor-8 (GDF-8)] is a mem-
ber of the TGF superfamily and is expressed predominantly
in skeletal muscle (31). Myostatin is synthesized as a precursor
protein, promyostatin, which undergoes dimerization and pro-
teolytic processing; promyostatin dimer is cleaved by furin
proteases to NH2-terminal propeptide fragments and COOH-
terminal disulfide-linked myostatin dimer (24). However, the
propeptides can still associate with myostatin dimer via
noncovalent bonds to form a latent complex that sequesters
functional myostatin by preventing its binding to the recep-
tor (24, 45). Myostatin acts through activin type IIB receptor
(ActRIIB) (24), and the signaling involves Smad2/3 tran-
scription factors (23, 57); furthermore, it influences the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which is
the key regulator of the anabolic and catabolic responses in
skeletal muscle (53).
Myostatin regulates the proliferation and differentiation of
myoblasts (23, 46); moreover, it also controls the activation
and proliferation of satellite cells, the stem cells of skeletal
muscle (29). Homozygous disruption of the myostatin gene
(31), administration of myostatin propeptide (25), or naturally
occurring myostatin gene mutations, e.g., in humans (38),
mouse (42), cattle (20), or sheep (10), result in widespread
increase of skeletal muscle mass (“double-muscled” pheno-
type). However, the effect of myostatin is not restricted to
skeletal muscle. Beside the autocrine and paracrine effects, it
can serve as an endocrine factor. Myostatin was reported to
influence the synthesis and secretion of IGF-1 (insulin-like
growth factor-1) in the liver, thereby regulating the amount of
circulating IGF-1 (51).
Several studies suggest that loss of myostatin or reduction
in active myostatin levels leads to increased insulin sensi-
tivity. Myostatin-null mice have increased muscle mass and
reduced body fat (14, 26, 32) and exhibit increased insulin
sensitivity (14), which depends on AMP-activated protein
kinase (55). Transgenic expression of myostatin propeptide
prevents diet-induced obesity and insulin resistance (56),
and the overexpression of follistatin-like 3, an inhibitor of
members of the TGF family (6), or inhibition of myostatin
by dominant-negative myostatin receptor (13) improves
insulin sensitivity. Furthermore, increased serum and mus-
cle myostatin levels were shown in insulin-resistant human
individuals (17).
The naturally occurring Compact mutation of the myostatin
gene arose in a selection program on protein amount and
hypermuscularity conducted at the Technical University of
Berlin (7, 8). Genetic analysis of the Hungarian subpopulation
of the hypermuscular Compact mice identified a 12-bp dele-
tion, denoted Mstn(Cmpt-dl1Abc), in the propeptide of the
promyostatin (42). The biologically active growth factor do-
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main of myostatin is unaffected by Compact mutation; there-
fore, the loss of myostatin activity cannot be explained by
disruption of the growth factor bioactive domain. However, the
mutation can lead to misfolding or defect in secretion and
mistargeting of mature myostatin (42). Additional modifier
genes should be present to determine the full expression of the
Compact phenotype; however, these modifier genes of the
special Compact genetic background have not yet been iden-
tified (47, 48). Furthermore, the molecular consequences of
Compact myostatin mutation, which can regulate muscle size
and metabolism, have not been examined. In this study, by
using a congenic wild-type mice strain with wild-type myosta-
tin and Compact genetic background, we could separately
study the effect of Compact myostatin mutation and genetic
background on morphology, metabolism, and signaling. The
Compact mice show several similarities compared with myo-
statin knockout animals; however, numerous alterations exist.
The Compact mutation decreased adiposity and improved
insulin sensitivity and glucose uptake, whereas the genetic
background exhibited the opposite effect. Importantly, here we
show that the mature myostatin protein is present in Compact
mice, and the 12-bp deletion in the sequence encoding the
propeptide decreased the formation of mature myostatin in
accordance with increased muscle mass.
MATERIALS AND METHODS
Animals. The Compact line carrying the 12-bp deletion in the
propeptide of promyostatin (Fig. 1A) was selected and inbred in a
long-term selection experiment in Berlin, Germany (8, 50). The
origin of the Hungarian subpopulation of the Compact line was
described earlier (3, 22). The BALB/c mice carrying wild-type
myostatin were obtained from the Biological Research Centre of
the Hungarian Academy of Sciences (Szeged, Hungary). The
Compact mice were crossed with BALB/c to introgress the wild-
type myostatin gene of BALB/c to Compact mice. The wild-type
myostatin allele was followed through five generations of repeated
backcrossing with the Compact line. Heterozygous animals of this
line in generation B5 were mated inter se to produce homozygous
wild-type animals with a Compact genetic background (denoted as
congenic wild-type animals). Genotyping for Compact myostatin
mutation [Mstn(Cmpt-dl1Abc)] was described earlier (42). Since
the Compact hypermuscular phenotype is stronger in males than
females (47), we performed the study on male 3- to 4-mo-old and
10-mo-old mice. Animal experiments conformed to the National
Institutes of Health’s Guide for the Care and Use of Laboratory
Fig. 1. Characterization of muscle phenotype of Compact, congenic wild-type, and BALB/c mice. A: schematic representation of the nonframeshift Compact
mutation in the propeptide region of promyostatin. B: representative T1-weighted small-animal MRI images of Compact, congenic wild-type, and BALB/c mice.
C: representative hindlimbs of 4-mo-old mice showing the different muscularity of mice strains. Bar, 10 mm. D: total glycogen amount and glycogen
concentration (glycogen amount/muscle weight) of hindlimb muscles. Data are presented as means SE; n  3 Compact, 6 congenic wild-type, and 4 BALB/c
mice [m. tibialis anterior (TA)]; n  6 Compact, 5 congenic wild-type, and 8 BALB/c mice [m. gastrocnemius (GAST)]; n  4 Compact, 6 congenic wild-type,
and 9 BALB/c mice [m. quadriceps femoris (QF)]. *P  0.05; **P  0.01; ***P  0.001.
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Animals (NIH Publication No. 85-23, revised 1996) and were
approved by the local Ethics Committee at the University of
Szeged.
Determination of tissue glycogen content. Nonfasting 3- to 4-mo-
old male mice were euthanized, and tissues were frozen in liquid
nitrogen. Total glycogen amount of the tissue samples was mea-
sured as glucose residues by hexokinase/glucose-6-phosphate de-
hydrogenase assay (Roche) following acidic hydrolysis, as de-
scribed earlier (22).
Periodic acid Schiff staining. Glycogen content of the liver samples
was visualized on 5-m-thin cryosections by periodic acid Schiff
(PAS) staining, as described previously (22).
Measurement of tissue alanine aminotransferase activity. Liver
samples of 3- to 4-mo-old male mice were frozen in liquid nitrogen,
and tissue homogenates were prepared as described at Western blot-
ting. The activity of alanine aminotransferase (ALT) enzyme of the
samples was determined by lactate dehydrogenase-coupled kinetic
colorimetric assay (Diagnosticum, Budapest, Hungary) in accordance
with the manufacturer’s instructions. Spectrophotometry was per-
formed with Fluostar Optima (BMG Labtech, Ortenberg, Germany).
Western blotting. To analyze protein expression levels, m. gastroc-
nemius and liver samples of 3- to 4-mo-old male animals were
homogenized at 4°C in a buffer [50 mM Tris·HCl (pH 7.6), 100 mM
NaCl, and 10 mM EDTA] supplemented with protease inhibitor
cocktail (Sigma-Aldrich), 1 mM natrium-orthovanadate, and 1 mM
natrium-fluoride. Following centrifugation at 4°C for 10 min at
11,000 g (Hettich Universal 320R, DJB; Labcare, Buckinghamshire,
UK) to remove cellular debris, the protein concentration of the
supernatants was determined by BCA kit (Thermo Scientific). The
samples were separated on 10% SDS-polyacrylamide gel under re-
ducing or nonreducing conditions and transferred onto Protran nitro-
cellulose membrane (Amersham, GE Healthcare). After incubation in
5% blocking agent (Bio-Rad), the membrane was incubated with
anti-phospho-Akt Ser473 (no. 4051; Cell Signaling Technology), anti-
phospho-Smad1/5/8 Ser463/465 (no. 9511; Cell Signaling Technology),
anti-phospho-Smad2 Ser465/467 (44-244G; Invitrogen), anti-Smad4
(sc-7966; Santa Cruz Biotechnology), anti-Akt (no. 4691; Cell Sig-
naling Technology), anti-myostatin (AB3239-I; Millipore), anti-
GDF8 propeptide (MAB7881; R&D Systems), anti-phospho-AS160
(no. 8881S; Cell Signaling Technology), anti-GLUT4 (no. 2213S;
Cell Signaling Technology), or anti-GAPDH (no. 2118; Cell Signal-
ing Technology) primary antibodies, followed by incubation with
appropriate horseradish peroxidase-conjugated anti-IgG secondary
antibody [P0448 and P0161 (DAKO), 112-035-003 (Jackson Immu-
noresearch)]. Mouse recombinant myostatin (788-G8; R&D Systems)
was used as a positive control. ECL reagent (Advansta, Menlo Park,
CA) was used for substrate detection, and the membrane was exposed
to X-ray film (AGFA) for visualization.
Intraperitoneal pyruvate tolerance test. Three- to four-month-old
male mice were fasted for 16 h before intraperitoneal pyruvate
tolerance test and had free access to water. Following the measure-
ment of baseline blood glucose levels, mice were injected with
intraperitoneal pyruvate (2 mg pyruvate/1 g body wt). Blood glucose
was measured from distal tail vein at 15, 30, 45, 60, 90, and 120 min.
All blood glucose measurements were performed by the AccuCheck
blood glucose monitoring system (Roche).
Intraperitoneal glucose and insulin tolerance tests. For intraperi-
toneal glucose tolerance test, male mice were fasted for 16 h and had
free access to water. The measurement of baseline blood glucose was
followed by intraperitoneal injection of D-glucose (2 mg glucose/1 g
body wt), and blood glucose was determined from distal tail vein at
30, 60, 90, and 120 min.
For intraperitoneal insulin tolerance test, animals were fasted for 5
h and had free access to water, and their baseline blood glucose was
measured. After the injection of intraperitoneal insulin bolus (1.0 U/1
kg body wt, Humulin R; Eli Lilly, Grootslag, The Netherlands), blood
glucose was measured from the distal tail vein at 15, 30, 45, 60, 90,
and 120 min. Blood glucose measurements were performed by the
AccuCheck blood glucose monitoring system (Roche).
Small-animal PET/MRI imaging using 2-deoxy-2-[18F]fluoro-D-
glucose. Ten-month-old male mice were injected with 7.0 0.2 MBq
of 18FDG (2-deoxy-2-[18F]fluoro-D-glucose) via the lateral tail vein in
0.2-ml volume. Fifty minutes after 18FDG injection, the animals were
anesthetized by 3% isoflurane with a dedicated small-animal anesthe-
sia device, and whole body PET scans (10-min static PET scans) were
acquired using the preclinical nanoScan PET/MRI system (Mediso).
To prevent movement, animals were fixed to a mouse chamber
(MultiCell Imaging Chamber; Mediso) and positioned in the center of
the field of view (FOV). For the determination of the anatomic
localization of the organs and tissues, T1-weighted MRI scans were
performed (3D GRE EXT multi-FOV, TR/TE 15/2 ms, FOV 70 mm,
NEX 2). PET volumes were reconstructed using a three-dimensional
Ordered Subsets Expectation Maximization (3D-OSEM) algorithm
(Tera-Tomo; Mediso). PET and MRI images were automatically
coregistered by the PET/MRI instrument’s acquisition software (Nu-
cline). Reconstructed, reoriented, and coregistered images were fur-
ther analyzed with InterView FUSION (Mediso) dedicated image
analysis software. Radiotracer uptake was expressed in terms of
standardized uptake values (SUVs). Ellipsoidal three-dimensional
volumes of interest (VOI) were manually drawn around the edge of
the tissue or organ activity by visual inspection using InterView
FUSION multimodal visualization and evaluation software (Mediso).
The standardized uptake value (SUV) was calculated as follows:
SUV  [VOI activity (Bq/ml)]/[injected activity (Bq)/animal weight
(g)], assuming a density of 1 g/ml. SUV mean is the average SUV
value within the volume of interest (VOI).
Statistical analysis. Statistical evaluations were performed by
1-way ANOVA and Newman-Keuls posttest (GraphPad Software).
All data are presented as means SE.
RESULTS
Body composition of Compact mice. The body weights of the
congenic wild-type mice carrying the wild-type myostatin gene
in Compact genetic background were higher than those of
BALB/c mice, but they were smaller than the Compact animals
(Table 1). We showed by MRI analysis that profound differ-
ences exist in body composition between the genotypes. The
qualitative analysis of T1-weighted MRI images revealed re-
markable enlargement of skeletal muscle tissues in Compact
mice. In the MRI images of congenic wild-type animals, the
spaciousness of fat tissues was clearly visualized (Fig. 1B). The
gross enhancement of hindlimb muscle mass was observable
(Fig. 1C). The absolute weights of individual hindlimb muscles
such as tibialis anterior, quadriceps femoris, and gastrocnemius
muscles were almost two times greater in Compacts compared
with congenic wild-type animals, and they were bigger in
congenic wild-type animals than in BALB/c mice (Table 1).
The muscle weight/body weight ratios showed the highest
values in Compacts and the lowest in congenic wild-type mice
(Table 1).
We found that the absolute weights of heart and kidney of
the Compact and congenic wild-type mice were comparable
and higher than that of BALB/c mice. The absolute weight of
abdominal fat increased by ~30% in 3- to 4-mo-old mice and
~50% in 10-mo-old congenic wild-type compared with Com-
pacts mice, and it was markedly lower in the BALB/c group
than in Compacts (Table 2). Liver/body weight ratio of Com-
pacts was smaller than that of congenic wild-type animals in
both ages (Table 2). Abdominal fat/body weight ratios were
comparable in Compact and BALB/c animals, and it was
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almost twofold higher in congenic wild-type mice (Table 2).
The weights of heart and kidney in proportion to body weight
were the smallest in Compacts and highest in BALB/c mice
(Table 2).
Glycogen accumulation is determined by the genetic back-
ground of Compact mice. Myostatin was reported to influence
the glycogen content of C2C12 myoblasts (9), and muscle
glycogen was reduced in type 2 diabetes mellitus (15). Previ-
ously, we have shown that Compact tibialis anterior muscle
contains more glycogen than that of BALB/c (22). To distin-
guish the role of Compact mutation and the Compact genetic
background in the regulation of glycogen stores, here we
compared the glycogen content of Compact, congenic wild-
type, and BALB/c muscles. We found that total glycogen
levels of Compact muscles were the highest, and the congenic
wild-type and BALB/c samples contained comparable and
smaller amounts of glycogen (Fig. 1D). However, the glycogen
concentration was the highest in BALB/c mice and displayed
no differences between Compact and congenic wild-type
groups (Fig. 1D).
Both the myostatin mutation and Compact genetic back-
ground influenced liver weight, and liver functions as a
glycogen store; therefore, we measured the glycogen con-
tent of the liver samples. Analyzing the total glycogen
amount and glycogen concentration, we did not observe
differences between congenic wild-type and Compact
groups; the glycogen content/liver weight ratio of BALB/c
animals was 2.5-fold smaller (Fig. 2A). The visualization
of glycogen by PAS staining verified the results of spectro-
photometry, and weaker staining was observed in BALB/c
samples (Fig. 2B).
Liver characteristics in Compact mice. It was reported that
knocking out of myostatin results in comparable absolute liver
weight, lower liver/body weight ratio, and decreased ALT
activity of the liver (18). We found that liver mass and
liver/body weight ratios are not increased in proportion to
skeletal muscle mass in Compact mice; therefore, we aimed to
assess whether ALT activity in proportion to body weight is
also reduced similarly to myostatin knockout animals. Our
data show that total liver ALT activity/body weight ratio
was the lowest in Compacts and the biggest in BALB/c mice
(Table 3).
Table 1. Absolute and normalized muscle weights
Compact Congenic wild-type BALB/c
3- to 4-Mo-old animals
Body weight, g 47.4  0.67b,e 40.8  1.76e 25.9  0.48
Muscle weight, mg
TA 113.8  1.64b,e 67.6  4.70e 45.9  0.88
GAST 350.3 8.15b,e 183.9  5.81e 140.5  2.14
QF 470.3  12.81b,e 246.1  6.71d 204.6  3.65
Muscle weight/body weight, mg/g
TA/body weight 2.4 0.04b,e 1.6  0.05c 1.8  0.04
GAST/body weight 7.4 0.13b,e 4.5  0.11e 5.4  0.08
QF/bw 9.9 0.22b,e 6.1  0.22e 7.9  0.11
10 Mo old animals
Body weight, g 50.4  0.53a,e 45.1  1.29e 31.4  0.88
Muscle weight, mg
TA 141.8  7.18b,e 69.5  2.45c 54.3  2.45
GAST 385.4 10.64b,e 185.0  2.45c 160.5  6.52
QF 476.0  14.09b,e 247.5  4.78 221.6 9.43
Muscle weight/body weight, mg/g
TA/body weight 2.8 0.14b,e 1.56  0.08 1.7 0.07
GAST/body weight 7.6 0.1b,e 4.13  0.09e 5.1  0.11
QF/body weight 9.4 0.22b,e 5.52  0.12e 7.0  0.12
Values are means SE (3- to 4-mo-old animals: n  9 Compact, 7
congenic wild-type, and 8 BALB/c mice; 10-mo-old animals: n  8 Compact,
12 congenic wild-type, and 8 BALB/c mice). TA, m. tibialis anterior; GAST,
m. gastrocnemius; QF, m. quadriceps femoris. The values of the Compact
group are significantly different from the congenic wild-type group: aP 0.01;
bP  0.001. The values of the Compact or congenic wild-type group are
significantly different from the BALB/c group: cP  0.05; dP  0.01; eP 
0.001.
Table 2. Absolute and normalized organ weights
Compact Congenic wild-type BALB/c
3- to 4-Mo-old animals
Organ weight, mg
Liver 1,792.0 43.45e 1,874.0  33.68e 1,158.0  31.55
Abdominal fat 672.8 59.07b,d 1,042.0  105.30e 271.9  20.21
Heart 153.8 4.71d 163.1  11.41d 121.4  3.17
Kidney 237.8 5.97e 250.6  11.76e 190.4  5.42
Organ weight/body weight, mg/g
Liver/body weight 37.8 0.81c,e 46.3  1.41 44.72 1.04
Abdominal fat/body weight 14.5 1.30c 25.3  1.76e 10.55  0.89
Heart/body weight 3.3  0.13c,e 3.9  0.12e 4.68  0.08
Kidney/body weight 5.0  0.11c,e 6.16  0.17e 7.35  0.17
10-Mo-old animals
Organ weight, mg
Liver 2,037.0 43.15a,e 2,213.0  65.05e 1,525.0  49.64
Abdominal fat 683.5 35.04b 1,236.0  156.3e 374.6  41.99
Heart 173.0 3.21e 178.2  5.67e 140.3  5.11
Kidney 266.9 3.63 300.3  12.03 290.6 21.00
Organ weight/body weight, mg/g
Liver/body weight 40.4 0.80c,e 49.3  1.29 48.6  0.82
Abdominal fat/body weight 13.6 0.75c 26.8  2.68e 12.1  1.48
Heart/body weight 3.4  0.07c,e 3.9  0.07e 4.5  0.11
Kidney/body weight 5.3  0.10a,e 6.6  0.11e 9.3  0.73
Values are means SE (3- to 4-mo-old animals: n 9 Compact, 7 congenic wild-type, and 8 BALB/c mice; 10-mo-old animals: n 8 Compact, 12 congenic
wild-type, and 8 BALB/c mice). The values of Compact group are significantly different from congenic wild-type group: aP  0.05; bP  0.01; cP  0.001.
The values of Compact or congenic wild-type group are significantly different from the BALB/c group: dP  0.01; eP  0.001.
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Next, we administered glucose precursor pyruvate to mea-
sure hepatic gluconeogenesis. The intraperitoneal pyruvate
tolerance test showed that hepatic gluconeogenesis increased in
Compact and congenic wild-type animals compared with
BALB/c animals. The area under the curve of blood glucose
concentrations during pyruvate tolerance test was comparable
in Compact and congenic wild-type mice, and it was lower in
BALB/c animals (Fig. 2C).
The Compact mutation of myostatin propeptide decreases
myostatin formation. The Compact Mstn(Cmpt-dl1Abc) muta-
tion in the myostatin gene eliminates amino acids 224–228 in
the propeptide and creates a new Phe residue (42). The Com-
pact mutation is toward the NH2 terminus from the furin
cleavage site, since promyostatin is proteolytically processed
by furin at the RSRR (263–266) site to give the active pro-
cessed myostatin (46). The Compact mutation is a nonframe-
shift 12-bp deletion, and the biologically active growth factor
domain is intact; therefore, functional myostatin formation
should be permitted. The presence of Compact mutation was
verified by sequencing the myostatin gene (data not shown).
Importantly, we were able to detect mature myostatin dimer in
Compact skeletal muscle (Fig. 3). Western blot analysis
showed that the level of mature myostatin dimer was the lowest
in Compact muscle and highest in BALB/c mice (Fig. 3) in
accordance with the skeletal muscle weights of the animals.
The anti-propeptide antibody could recognize the mutant
propeptide, and the expression level of propeptide was
proportional to myostatin level when the genotypes were
compared; the lowest amount was detected in Compact
samples (Fig. 3).
Effect of Compact myostatin mutation and genetic back-
ground on signaling. Myostatin is expressed and secreted
predominantly by skeletal muscle; however, as an endocrine
factor, it can influence the signal transduction of liver (51). We
could detect the mature myostatin; therefore, we investigated
myostatin signaling in both skeletal muscle and liver. Despite
low levels of myostatin protein in Compact skeletal muscle, the
level of phospo-Smad2 was the highest when the genotypes
were compared (Fig. 4B), suggesting the potential role of other
TGF members in Smad2 activation. The specificity of the
anti-p-Smad2 antibody is shown in Fig. 4A. Phospho-Smad2
levels of the liver samples were the lowest in BALB/c mice and
the highest in Compacts (Fig. 4C).
Both the Smad2/3 signaling mediated by TGF family
members and the Smad1/5/8 pathway mediated by bone mor-
phogenic proteins (BMPs) converge on the common mediator
Smad4. The balance between these competing pathways is
required to maintain muscle mass; the BMP-mediated Smad1/
5/8 pathway is the fundamental hypertrophic signal in mice,
which is dominant over myostatin signaling, and Smad4 defi-
ciency induces muscle atrophy (37). Furthermore, Smad1/5/8
signaling is an important regulator of liver homeostasis (11,
41). The level of phospho-Smad1/5/8 was significantly higher
in muscles of Compacts compared with congenic wild-type
samples (Fig. 4B). However, we have not found any significant
differences in phospho-Smad1/5/8 levels of liver samples be-
tween the genotypes (Fig. 4C). Furthermore, no differences
were observed between either muscular (Fig. 4B) or hepatic
(Fig. 4C) Smad4 levels.
Myostatin was reported to inhibit the PI3K/Akt pathway
(53); therefore, we determined the phosphorylation level of
Akt. The phospho-Akt Ser473/Akt ratio of congenic wild-type
liver was lower than that of Compact and comparable with
Table 3. Fasting blood glucose levels and hepatic ALT
activity
Compact Congenic wild-type BALB/c
Fasting blood glucose, mM/l
3- to 4-Mo-old animals 5.81 0.67 5.81  0.64 5.38  0.69
10-Mo-old animals 5.20 0.25 5.07  0.16 4.82  0.28
Total hepatic ALT activity·g body wt1, U/g
3- to 4-mo-old animals 0.12 0.008*‡ 0.15  0.006† 0.18  0.002
Values are means SE [3- to 4-mo-old animals: n  3 Compact, 8
congenic wild-type, and 3 BALB/c mice; 10-mo-old animals: n  5 Compact,
3 congenic wild-type, and 6 BALB/c mice for the fasting blood glucose; n 
4 in each group for alanine aminotransferase (ALT) activity]. The values of
Compact group are significantly different from congenic wild-type group:
*P  0.05. The values of Compact or congenic wild-type group are signifi-
cantly different from the BALB/c group: †P  0.01; ‡P  0.001.
Fig. 2. Characterization of the Compact, congenic wild-type, and BALB/c
livers. A: total glycogen amount and glycogen concentration of the liver
samples determined by spectrophotometry (n  4 Compact, 5 congenic
wild-type, and 4 BALB/c mice). B: representative periodic acid Schiff (PAS)-
stained images show glycogen content of the liver. Scale bar, 200 m. C:
intraperitoneal (ip) pyruvate tolerance test of 3- to 4-mo-old mice (n  3
Compact, 5 congenic wild-type, and 4 BALB/c mice). Area under the curve
(AUC) values are presented in bar diagrams. Data are reported as means SE.
*P  0.05; ***P  0.001.
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BALB/c values (Fig. 4C). In contrast, phospho-Akt Ser473/Akt
ratios were higher in Compact and congenic wild-type muscles
compared with BALB/c samples, in accord with myostatin
levels (Fig. 4B).
AS160 (Akt substrate of 160 kDa), a Rab GTPase-activating
protein, can regulate the translocation of GLUT4 glucose
transporter to the plasma membrane of insulin-sensitive cells
(21). The level of phospho-AS160 was lower in congenic
wild-type muscle samples compared with those of Compact or
BALB/c mice (Fig. 4D). The GLUT4 expression showed equal
levels in Compact and congenic wild-type animals, and the
level was lower in BALB/c samples (Fig. 4D).
Glucose tolerance and insulin sensitivity are improved by
Compact myostatin mutation and reduced by Compact genetic
background. As reported previously, knocking out of myosta-
tin increases glucose tolerance and insulin sensitivity (14, 55),
and fed and fasting glucose levels in myostatin knockout mice
were not significantly different from controls (32). Since the
Compact mice were hypermuscular and had reduced abdomi-
nal fat, we examined whether Compact mice showed altera-
tions in glucose metabolism. Because age is reported to influ-
ence glucose tolerance (2, 28), we compared whole body
glucose tolerance and insulin sensitivity from both young (3- to
4-mo-old) and middle-aged (10-mo-old) groups of mice. Our
results did not show any significant changes in fasting blood
glucose levels comparing Compact mice with age-matched
congenic wild-type and BALB/c animals (Table 3); however,
the response to exogenous glucose revealed differences be-
tween genotypes. Compact and BALB/c mice showed greater
glucose tolerance compared with age-matched congenic wild-
type strain. The area under the curve of blood glucose concen-
trations during the glucose tolerance test was significantly
higher in congenic wild-type mice compared with age-matched
Compact and BALB/c (Fig. 5A). We performed insulin toler-
ance tests to measure blood glucose changes following insulin
administration. Insulin treatment reduced blood glucose levels
in all groups of mice, indicating the insulin responsivity.
Congenic wild-type mice showed weaker insulin sensitivity
compared with Compact and BALB/c groups. The area under
the curve value during the insulin tolerance test was signifi-
cantly higher in congenic wild-types than in Compact and
BALB/c mice at both ages (Fig. 5, C and D). Both glucose
tolerance and insulin sensitivity tests showed comparable re-
sults between age-matched Compacts and BALB/c mice (Fig.
5, A–D).
To test the effect of aging on glucose tolerance and
insulin sensitivity, the area under the curve values were
compared. The area under the curve of blood glucose
concentrations during glucose tolerance tests of 10-mo-old
Compacts was significantly higher than that of 3- to 4-mo-
old animals (1,154  31.5 vs. 943.3  86.3, P  0.0318);
no alterations were observed comparing young and middle-
aged congenic wild-type or BALB/c groups. The area under
the curve values during insulin tolerance tests of young
animals were not significantly different from middle-aged
groups, although they tended to be smaller in all three
genotypes.
Compact mutation increases 18FDG uptake in skeletal mus-
cle, liver, and adipose tissue. The Compact mutation and
genetic background affected glucose tolerance and insulin
sensitivity; therefore, we evaluated glucose uptake in dif-
ferent tissues with known insulin responsiveness using
small-animal PET/MRI imaging. By the quantitative analy-
sis of decay-corrected 18FDG-PET images, we found signif-
icant differences in the SUV mean of the selected organs 50
min after tracer injection (Fig. 6). The 18FDG accumulation
of the skeletal muscle was comparable in Compacts and
BALB/c animals, and moderate uptake was observed in
congenic wild-type animals. The radiotracer uptake of white
adipose tissue showed similar results as skeletal muscle,
mild uptake was observed in the congenic wild-type mice,
and it was approximately twofold higher in Compact and
BALB/c animals. The liver of Compact mice showed the
Fig. 3. Myostatin level in skeletal muscle of Compact,
congenic wild-type, and BALB/c mice. M. gastrocnemius
protein extracts were subjected to SDS-PAGE and blotted
with anti-myostatin or anti-propeptide antibody. Represen-
tative images are shown. Note the presence of mature
myostatin dimer and myostatin propeptide in Compact sam-
ples. Mouse recombinant myostatin was used as a positive
control, and muscle homogenates of myostatin knockout
(KO) mice served as a negative control. Differences in
glycosylation may cause altered electrophoretic mobility.
Bar diagrams show the quantification of the results. Data are
reported as means  SE; n  5 Compact, 5 congenic
wild-type, and 6 BALB/c mice. *P  0.05; **P  0.01;
***P  0.001.
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highest SUV mean, which was followed by the congenic
wild-type and BALB/c groups.
DISCUSSION
Myostatin is a TGF family member that is expressed and
secreted predominantly by skeletal muscle. The function of
myostatin appears to be conserved across species, since muta-
tions in the myostatin gene induce bigger muscles in human,
mice, cattle, dogs, and sheep (10, 20, 37, 38, 42). The Compact
mice arose during a long-term selection program to reach the
maximal hypermuscularity (7). The major gene responsible for
the hypermuscular phenotype was mapped on chromosome 1
(49), and after the discovery of myostatin gene (31) the
Mstn(Cmpt-dl1Abc) deletion in the propeptide region of the
mouse myostatin was identified as the causative mutation
responsible for the Compact phenotype (47). Due to selection
for hypermuscularity, the Compact line, in addition to achiev-
ing homozygosity for the Mstn(Cmpt-dl1Abc) mutation, also
accumulated modifier alleles that were involved in the full
expression of the phenotype (47, 48). Markers on several
chromosomes (chromosomes 1, 3, 5, 7, 11, 16, and X) showed
linkage with the putative modifiers, and the strongest associa-
Fig. 4. Alterations of phospho (p)-Smad2, p-Smad1/5/8, p-Akt, and p-AS160 (Akt substrate of 160 kDa) signaling in the different mouse strains. A: m.
gastrocnemius homogenates (50 g protein/lane), mouse brain (40 g protein/lane), and mouse liver (60 g protein/lane) samples of Compact mice were
subjected to SDS-PAGE and developed by anti-p-Smad2 antibody to establish the specificity of the antibody. Brain samples served as a positive control, and
the negative control was incubated with only the secondary antibody. p-Smad2 was detected at the predicted molecular weight in either mouse skeletal muscle,
liver, or positive control samples. Note the low level of p-Smad2 in skeletal muscle compared with liver and brain tissues. B–D: Western blot experiments of
Compact, congenic wild-type, and BALB/c samples indicate the activity of signaling pathways in M. gastrocnemius (B and D) and liver (C) tissues. Bar diagrams
show the quantifications of the results. Data are reported as means  SE; n  3 in each group. *P  0.05; **P  0.01.
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tion was found for markers on chromosomes 16 and X (47, 48).
Myogenin is a candidate on chromosome 1 (48), which has
been proposed as a downstream target of myostatin (23).
Candidates localized on chromosome 7 are MyoD1, a key
regulator of myogenesis, and Pcsk6 (protein convertase subtil-
isin/kexin type 6), which is involved in proteolytic processing
of TGF members. Further candidates are chordin on chromo-
some 16, which binds BMPs and sequesters them in a latent
complex, and androgen receptor on chromosome X (47).
Moreover, little is known about the detailed phenotype of
Compact mice, and the molecular consequences of Compact
mutation are completely unclear. We and others have reported
earlier that the Compact mice are hypermuscular (3, 22, 35),
and cellularity of the Compact skeletal muscles shows in-
creased ratio of glycolytic fibers in rectus femoris, longissimus
dorsi (35), and tibialis anterior (3, 22) muscles. Decreased
specific force (1) and reduced calcium release from sarcoplas-
mic reticulum (5) were reported in Compact muscles.
To separately study the effect of Compact myostatin muta-
tion and Compact genetic background, we generated a con-
genic wild-type strain carrying wild-type myostatin in the
Compact genetic background. We introgressed the wild-type
myostatin gene of BALB/c to Compact mice to generate the
congenic wild-type line, and we used BALB/c mice as a
wild-type control for the reasons listed by Baán et al. (3).
Briefly, this inbred line was used for mapping the Compact
myostatin mutation and the modifier genes (42), and their
muscle characteristics are similar to those of C57BL/6 mice.
We have found that both the Compact myostatin mutation and
the Compact genetic background account for determination of
skeletal muscle size. The Compact mutation resulted in a
disproportionate increase in skeletal muscle mass, leading to
increased muscle/body weight ratios and decreased internal
organ/body weight ratios. The Compact mice are weighted and
hypermuscular compared with both congenic wild-type and
BALB/c animals. Interestingly, the normalized muscle weights
of congenic wild-type animals are the smallest despite their
increased absolute muscle weights compared with BALB/c
mice; therefore, other organs should be involved in accretion of
body weight of congenic wild-type animals.
Beyond the regulation of muscularity, myostatin was shown
earlier to influence the size of internal organs. Knocking out of
myostatin resulted in decreased weight of fat, liver, and kidney
Fig. 5. Glucose tolerance and insulin sensitivity are improved by Compact myostatin mutation and reduced in congenic wild-type mice. Intraperitoneal (ip)
glucose tolerance (A and B) and insulin sensitivity tests (C and D) of 3- to 4-mo-old (A and C) and 10-mo-old animals (B and D). Area under the curve (AUC)
values are presented in bar diagrams. Data are reported as means  SE. *P  0.05 and **P  0.01; n  3 Compact, 7 congenic wild-type, and 3 BALB/c mice
(A), n  7 Compact, 3 congenic wild-type, and 6 BALB/c mice (B), n  3 Compact, 3 congenic wild-type, and 4 BALB/c mice (C), and n  6 Compact, 4
congenic wild-type, and 4 BALB/c mice (D).
Fig. 6. Compact mutation increases 18FDG (2-deoxy-2-[18F]fluoro-D-glucose)
uptake. Quantitative analysis of 18FDG uptake of selected tissues in Compact,
congenic, and BALB/c mice 50 min after tracer injection. Data are presented
as means  SE; n  3 Compact, 4 congenic wild-type, and 4 BALB/c mice
(skeletal muscle, liver); n 4 in each group (white adipose tissue). *P 0.05;
**P  0.01.
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as proportional to body weight (18, 19, 26, 32). The absolute
weight of heart increased; however, heart weight/body weight
ratio did not change (19, 26). Bünger et al. (8) introgressed the
Compact mutation into a mouse line with extreme growth
(DUHi). The Compact mutation in the DUHi background
decreased the absolute size of liver, heart, and kidney (8); in
contrast, based on our study, the Compact mutation did not
affect them in the Compact background, indicating the impor-
tance of genetic background in the manifestation of the phe-
notype. However, the Compact mutation resulted in hypermus-
cularity in both the DUHi (8) and Compact backgrounds as
well. Similarly to myostatin knockouts, the liver/body weight
ratio set point is reduced in Compacts. By testing the enzy-
matic functions of the liver, despite the smaller liver weight/
body weight ratio of Compacts, the hepatic gluconeogenesis
was comparable with congenic wild-type animals following
exogenous pyruvate. The tissue ALT activity of the liver was
reduced by Compact myostatin mutation similarly to knocking
out of myostatin (18).
Myostatin was reported to affect glucose metabolism; how-
ever, the fed and fasting glucose levels of myostatin knockout
male mice were not different from controls (32). Similarly to
these observations, fasting blood glucose levels of Compact
mice did not change compared with age-matched congenic
wild-type and BALB/c animals. Furthermore, myostatin-null
mice have reduced body fat beyond the increased muscle mass
and exhibit increased insulin sensitivity (14, 55). Here, we showed
that Compact mutation increased muscularity and decreased adi-
posity similarly to myostatin knockout mice, whereas the genetic
background had the opposite effect, increasing adiposity and
decreasing skeletal muscle mass/body weight ratios. As a conse-
quence of these alterations in body composition, the Compact
mutation improved whole body glucose tolerance and insulin
sensitivity, whereas the genetic background decreased them.
The Compact mutation increased the 18FDG radiotracer uptake
into all investigated organs (white adipose tissue, skeletal
muscle, and liver). The phosphorylation of AS160 was shown
to regulate the translocation of GLUT4 to the plasma mem-
brane (21, 36). However, the Compact mutation did not influ-
ence the amount of GLUT4 in skeletal muscle, but the in-
creased p-AS160 level in Compact animals might contribute to
the increased glucose uptake by enhancing the GLUT4 trans-
location to the plasma membrane.
Besides the regulation of insulin sensitivity and glucose
tolerance, the Compact genetic background has a role in the
regulation of tissue glycogen content. It has opposite impacts
on skeletal muscle and liver by decreasing the glycogen level/
tissue weight ratio in muscle and increasing it in the liver.
These alterations can be at least partially the consequences of
decreased glucose uptake into muscle and increased glucose
uptake into liver. Consistent with these results, reduced muscle
glycogen was reported in type 2 diabetes mellitus (15). The
Compact mutation itself did not affect the glycogen level/tissue
weight ratio in either muscle or liver tissue; however, myosta-
tin treatment was found to reduce the glycogen content of
C2C12 myoblasts (9).
Age was shown to affect glucose metabolism; however, no
difference was reported in glucose clearance rate comparing 6-
and 12-mo-old BALB/c mice (33). Consistent with these re-
sults, the glucose tolerance of BALB/c animals did not change
with age (3–4 vs. 10 mo old) in our study. Interestingly, aging
reduced glucose tolerance of Compact mice without any sig-
nificant alteration in sensitivity for exogenous insulin.
Although the Compact mutation was identified in 1998 (42),
its precise molecular effects have not yet been published. The
Compact mutation is a nonframeshift deletion in the propep-
tide; therefore, it raised the possibility that the mature myosta-
tin is present in Compact mice. Here, we have shown that the
Compact mutation allows the formation of mature myostatin;
however, the amount of myostatin was lower in Compact
skeletal muscle, in accordance with increased muscle mass.
Most of the naturally occurring myostatin mutations led to the
development of an early STOP codon; however, some muta-
tions were shown to be associated with altered proteolysis of
promyostatin (4, 43) permitting myostatin formation.
The specific functions of the propeptides of TGF superfam-
ily members are largely unknown; however, they can play a
role in targeting and inactivation of the biological active
COOH-terminal part, and they have an impact on binding
properties to extracellular components. All of these functions
of myostatin propeptide can be disturbed by Compact muta-
tion. It was reported that BMP-7 propeptide binds fibrillin-1
(39), BMP-5 propeptide binds fibrillin-1 and -2 (39), and the
interaction between myostatin propeptide and perlecan was
identified (40). The interaction of propeptide and myostatin is
relevant in vivo, with a majority (70%) of myostatin in serum
bound to its propeptide (16). The amino acid sequence of
GDF-11 (growth/differentiation factor-11) is 90% homologous
to myostatin in the carboxy-terminal mature region of the
protein, and like myostatin, GDF-11 can signal through Ac-
tRIIB (30), and GDF-11 administration leads to activation of
Smad2 signaling (12, 34). Myostatin propeptide may bind and
inhibit GDF-11 as well as myostatin (30); therefore, the mutant
propeptide of Compact mice might disturb not only myostatin
but, e.g., GDF-11 signaling as well.
Despite the low level of myostatin protein in Compact
skeletal muscle, the level of phospo-Smad2 was the highest
when the genotypes were compared, suggesting the potential
role of other TGF members (e.g., GDF-11) or HGF (hepato-
cyte growth factor) in Smad2 activation. HGF is a regulator of
satellite cells (44) and transmits signals through Smad2/3. The
BMP-mediated Smad1/5/8 signaling is an important regulator
of skeletal muscle mass (37, 52), hepatocyte proliferation, and
liver regeneration and function (11, 41). Comparing the geno-
types, phospho-Smad1/5/8 levels show the same pattern as
tissue weight/body weight ratios in both skeletal muscle and
liver, suggesting the impact of Smad1/5/8 signaling on regu-
lation of skeletal muscle and liver size. The BMP inhibitor
chordin was proposed as a modifier gene in Compact mice (48)
that can influence the activity of BMP pathway by binding and
modulating the effect of BMPs (54). Interestingly, the elevated
phospho-Smad1/5/8 levels can derive not just from BMPs,
since TGF was reported to stimulate the phosphorylation of
Smad1/5 through a noncanonical mechanism (27).
The Compact mice represent a complex system consisting of
a natural mutation in the propeptide of promyostatin and
additional modifier genes. The Compact mice show several
similarities compared with myostatin knockout animals; how-
ever, numerous alterations exist due to the redundant function
of propeptide and the presence of the specific Compact genetic
background. Myostatin propeptide may bind and inhibit
GDF-11 as well (30); therefore, the effect of Compact propep-
E158 METABOLIC ALTERATIONS IN Compact MICE
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00216.2016 • www.ajpendo.org
Downloaded from www.physiology.org/journal/ajpendo by ${individualUser.givenNames} ${individualUser.surname} (160.114.032.229) on July 3, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
tide cannot be restricted to myostatin signaling. Our analysis
has shown that the modifier genes of the genetic background
can strengthen the effect of Compact myostatin mutation, or
they can compensate for each other. Further analysis of the
biological effect of Compact mutation and the identification of
modifier genes may provide a route to additional upstream and
downstream factors involved in the regulation of skeletal
muscle size and metabolism.
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